Dermata Therapeutics Inc. (NASDAQ: DRMA) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT DERMATA THERAPEUTICS INC.

Dermata Therapeutics Inc. (NASDAQ: DRMA)
Listen to this Section


$1.20
-0.0500 ( -4.00% ) 37.0K

Dermata Therapeutics Inc is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to develop and formulate singular and combination products that are able to target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases.

Clinical Trial Pipeline Stages


Drug Name Stage
DMT310DetailsAcne vulgaris, Acne Phase 3
DMT310DetailsPsoriasis Failed
DMT310DetailsPapulopustular rosacea Failed

Market Data


Open $1.20
Previous Close $1.25
Volume 37.0K
Market Cap $5.11M
Day Range $1.20 - $1.33
52 Week Range $1.10 - $8.00
Shares Outstanding 4.02M
Change % -4.00%
Net Change ▼ -0.0500
Insider Ownership 0.00%
Exchange NASDAQ
SectorHealthcare
IndustryBiotechnology: Pharmaceutical Preparations
IPO Year2021
CountryUnited States
UnderwriterMaxim Group LLC, Brookline Capital Markets, more

Insider Ownership Transactions

Total Amount Purchased: -320,000.00

Date Type Amount Purchased Purchaser
2024-01-05 Sale -10000.00 Mento Steven J

SEC Filings


Form Type Description Pages Date
8-k 8K-related 16 Nov 14, 2025
10-q Quarterly Reports 54 Nov 14, 2025
8-k 8K-related 13 Sep 17, 2025
8-k 8K-related 13 Sep 10, 2025
8-k 8K-related 13 Aug 25, 2025
10-q Quarterly Reports 54 Aug 13, 2025
8-k 8K-related 15 Aug 13, 2025
8-k 8K-related 14 Jul 30, 2025
8-k 8K-related 13 Jul 16, 2025
8-k 8K-related 13 Jul 07, 2025

Latest News


× Before browsing our site, please accept our cookies policy